Telix Resubmits NDA for Brain Cancer Imaging Agent TLX101-Px to FDA
ByAinvest
Monday, Mar 16, 2026 6:00 am ET1min read
TLX--
Telix Pharmaceuticals has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer, to the FDA. The resubmission addresses the complete response letter received in April 2025, which requested additional confirmatory clinical evidence. Telix believes it has appropriately addressed the CRL and filed a marketing authorisation application for TLX101-Px in Europe. The company reported a 56% increase in revenue to $803.8 million in 2025 and provided guidance for 2026 revenue in the range of $950 million to $970 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet